Boehringer Ingelheim (BI) and BeiGene, a Beijing, China-headquartered clinical-stage biopharmaceutical company focused on immuno-oncology, have signed a commercial supply agreement for tislelizumab, BeiGene’s investigational anti-PD-1 antibody.

Tislelizumab will be manufactured in BI’s biopharmaceutical manufacturing facility in Shanghai as part of a marketing authorization holder trial project initiated by the two companies.

Under the agreement, BI will manufacture tislelizumab in China under an exclusive multi-year arrangement, with contract extension possible. In addition, BeiGene also obtained certain preferred rights for future capacity expansion by BI in China.

Source: BeiGene